Entering text into the input field will update the search result below

BioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And Nektar


  • Omeros Corporation rallied due to strong fundamentals of OMS-721.
  • The concerns regarding Omidria reimbursement are vanquished as the pass-through status is extended.
  • Unum Therapeutics went IPO to raise $69M for the innovation of the specialized form of TCR.
  • Unnum can be a potential acquisition target by its partner Seattle Genetics. The insiders already loaded up shares. FDA policies against painkillers improve the prospects of NKTR-181 for Nektar Therapeutics.
  • This is a sample of the Integrated BioSci Rounds Report that we wish to share with our readers.

"None of us likes to admit to himself that he has been wrong." - The Father of Growth Investing (Philip Fisher)

Trading Analytics

Welcome to another edition of Integrated BioSci Rounds Report for April 3, 2018. As usual, we'll elucidate notable trading analytics for the day, recent insider transactions, and interesting market developments. Without further ado, let's dive into the first notable trades with Omeros Corporation (NASDAQ:NASDAQ:OMER) - a bioscience focusing on the therapeutics innovation and commercialization to treat both large as well as rare diseases. Today, the company traded $1.36 higher at $12.15 for 12.60% profits.

Of note, the recent concerns about the Center for Medicare and Medicaid Services (CMS) reimbursement for lead product Omidria (phenylephrine and ketorolac 1%/0.3%) for maintaining the pupil size and reducing post-op pain during cataract surgery. In response, the market overly worried that Omidria will lose its pass-through status so that eyes surgeons (ophthalmologists) can only charge $992 for the operation (rather than the usual $492 on top). In response to the potential of the new bill being pass to extend the pass-through coverage, the shares rallied over 35% on March 22, 2018, as investors bet that the said bill will go through. As it turned out, that is exactly the case as the firm filed their 8-K on March 23 with the following update:

On March 23, 2018, President Trump signed into law the Consolidated Appropriations Act of 2018. A bipartisan-supported provision in the Act extends pass-through reimbursement status for a small number of drugs used during procedures performed on Medicare Part B fee-for-service patients for an additional two years, effective Oct. 1, 2018, through Sep. 30, 2020. The drugs that qualify for this extension are those for which previously existing pass-through reimbursement status expired on Dec. 31, 2017, and which became included as part of the packaged procedural payment as of Jan. 1, 2018. Omidria is one of

Author's Notes: We're honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 441%, 107%, 166%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Subscribe to our marketplace now to lock in the current price and save money for the future.

If you are a real-time follower, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the two-week free trial of Integrated BioSci Investing.

This article was written by

BioSci Capital Partners profile picture
The #1 Biotech Service for Growth Investing and Catalyst Power Trading

As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading. 

Since inception, our flagship portfolio has delivered over 
31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.

Check out some of
our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.

In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis.
The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.

Follow us for the latest research. And,
take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!

Check out Dr. Harvey’s
LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.